Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Expression of MDM2 during mammary tumorigenesis.

Pinkas J, Naber SP, Butel JS, Medina D, Jerry DJ.

Int J Cancer. 1999 Apr 12;81(2):292-8.

2.

Function and dysfunction of the human oncoprotein MDM2.

Deb SP.

Front Biosci. 2002 Jan 1;7:d235-43. Review.

PMID:
11779693
3.

Alternative and aberrant splicing of MDM2 mRNA in human cancer.

Bartel F, Taubert H, Harris LC.

Cancer Cell. 2002 Jul;2(1):9-15. Review.

4.

The mdm2 proto-oncogene.

Haines DS.

Leuk Lymphoma. 1997 Jul;26(3-4):227-38. Review.

PMID:
9322885
5.

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines.

Pfeffer U, Fecarotta E, Arena G, Forlani A, Vidali G.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):99-105. Review.

PMID:
8603053
6.

MDM2 and MDM4 splicing: an integral part of the cancer spliceome.

Jeyaraj S, O'Brien DM, Chandler DS.

Front Biosci (Landmark Ed). 2009 Jan 1;14:2647-56. Review.

PMID:
19273224
7.

Cell cycle regulatory functions of the human oncoprotein MDM2.

Deb SP.

Mol Cancer Res. 2003 Dec;1(14):1009-16. Review.

8.

MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides.

Bartel F, Harris LC, Würl P, Taubert H.

Mol Cancer Res. 2004 Jan;2(1):29-35. Review.

9.

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

Rayburn E, Zhang R, He J, Wang H.

Curr Cancer Drug Targets. 2005 Feb;5(1):27-41. Review.

PMID:
15720187

Supplemental Content

Support Center